Fibrate therapy: Safety considerations

Current Opinion in Lipidology

Volumn 18, Issue 6, 2007, Pages 702-704

  Usman, Muhammad ^a   Peter, Rajesh ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LY 518674; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSLIPIDEMIA; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 36048946945     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f1ed84     Document Type: Editorial

References (7)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
2. Davidson MH, Armani A, Mckenne JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99:3c-18c.
3. Keech A, Simes RJ, Barter P, et al. Effect of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
4. Grundy SM, Vega GL, Yaun Z, et al. Effectiveness and tolerability of simvastatin and fenofibrate for combined hyperlipidemia (the SAFARI TRIAL). Am J Cardiol 2005; 95:462-468.
5. Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidaemia. J Clin Hypertens (Greenwich) 2006; 8:35-41.
6. Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45:485-493.
7. Brown WV. Expert commentary: the safety of fibrates in lipid lowering therapy. Am J Cardiol 2007; 99:19c-21c.